is a Data Source.
CLUE (formerly known as the Connectivity Map or CMap 2.0) is a comprehensive resource for connecting drugs, genes, and diseases through large-scale perturbational data. Built and maintained by the Broad Institute, CLUE provides access to over 1.3 million gene expression profiles from the LINCS L1000 assay, covering more than 42,000 perturbagens (drugs, genetic reagents, and other compounds) tested across multiple cell lines. The platform enables researchers to discover connections between diseases, drugs, and biological mechanisms through gene expression signatures.
drug discovery, genomics, biomedical, systems biology
Warning: No license entered
Unknown
Unknown
| ID | Name | URL | Category | Format | Description |
|---|---|---|---|---|---|
| bioteque.embeddings | Bioteque Embeddings | embeddings | Product | ❔ | Network embeddings of the Bioteque gr... |
CLUE (Connectivity Map 2.0) is a next-generation platform for drug discovery and biological research that builds upon the original Connectivity Map project. Developed and maintained by the Broad Institute of MIT and Harvard, CLUE provides unprecedented access to large-scale perturbational gene expression data.
CLUE hosts the world’s largest collection of perturbational gene expression profiles, with over 1.3 million profiles generated using the LINCS L1000 high-throughput gene expression assay. The platform covers:
The CLUE platform provides free access to:
CLUE offers sophisticated tools for:
CLUE enables researchers to:
CLUE provides multiple data access points through clue.io/data, including:
CLUE represents the evolution and expansion of the original Connectivity Map (CMap) project. While the original CMap provided proof-of-concept with approximately 7,000 expression profiles, CLUE has scaled the approach by orders of magnitude, providing a much more comprehensive resource for connecting perturbational biology.
Created: August 12, 2025 | Last modified: October 07, 2025